• Ashish Kumar Kakkar and Neha Dahiya.
• Dept. of Pharmacology, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India. Electronic address: drashishkakkar@gmail.com.
• Eur. J. Intern. Med. 2015 Mar 1; 26 (2): 89-94.

AbstractObesity is a growing epidemic and a major contributor to the global burden of disease. Obesity strains the healthcare systems and has profound economic and psychosocial consequences. Historically, pharmacotherapy for obesity has witnessed the rise and fall of several promising drug candidates that had to be eventually withdrawn due to unacceptable safety concerns. Currently four drugs are approved for chronic weight management in obese adults: orlistat, lorcaserin, phentermine/topiramate extended release and naltrexone/bupropion extended release. While lorcaserin and phentermine/topiramate were approved by US Food and Drug Administration (FDA) in 2012, after a gap of 13 years following the licensing of orlistat, naltrexone/bupropion has been recently approved in 2014. This review provides a brief overview of these current therapeutic interventions available for management of obesity along with the evidence of their safety and efficacy. Additionally, several novel monotherapies as well as combination products are undergoing evaluation in various stages of clinical development. These therapies if proven successful will strengthen the existing armamentarium of antiobesity drugs and will be critical to combat the global public health crisis of obesity and its associated co-morbidities.Copyright © 2015 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.

24 keywords...

hide…